CanPharma News Feed

No more posts

The active ingredient, haloperidol, is a highly potent antipsychotic (neuroleptic) drug that is approved to treat acute mania, acute chronic schizophrenia and for tic disorders (Tourette’s syndrome). However, consumption of the drug is associated with severe side effects. These include long-term movement disorders and late dyskinesias.

Researchers from Lagos have now been able to show in animal models that the simultaneous administration of haloperidol and cannabidiol (CBD) could prevent these side effects.

How does Haloperidol work?

The nerve cells in the brain communicate via different neurotransmitters (messenger substances). These can be roughly divided into two groups: While some messenger substances such as norepinephrine have an activating, excitatory and stimulating effect, other messenger substances such as serotonin, the “happiness hormone”, trigger calming and attenuating effects.

Haloperidol is prescribed when an excess of the messenger substance, dopamine, is detected in patients. Dopamine is also known as the “happiness hormone”. An excess of this can trigger schizophrenia, psychosis, delusions and loss of reality.

The active substance haloperidol binds to the dopamine receptors and blocks them so that the dopamine signals are not transmitted. As a result, the high levels of dopamine normalise.

In Parkinson’s disease, patients show a lack of dopamine so that the body’s movement patterns are disturbed. Since haloperidol blocks the dopamine signals, movement disorders may also occur. These are known as extrapyramidal motor disorders and can manifest themselves in the form of an urge to move, restlessness and involuntary movements.

Haloperidol in combination with cannabidiol

The researchers investigated the effects of CBD on haloperidol-induced extrapyramidal motor disorders. There were a total of six experimental groups with rats receiving different combinations of oral cannabidiol with 5 mg/kg haloperidol.

The researchers concluded from the results that haloperidol in combination with CBD could alleviate motor impairments and prevent long-term movement disorders such as acute dystonic disorders.


A report by “Medical Xpress” states that roughky 75,000 Australians are suffering from a chronic bowel disease known as Crohn’s disease, or ulcerative colitis. These are caused by inflammation in the gastrointestinal tract. As a result, those affected often suffer from diarrhoea, constipation, pain and weight loss, which has an enormous impact on the quality of their everyday life.

The report also states that recent research by the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney shows a quarter of those affected in Australia use illegal cannabis for treatment. A total of 838 patients were interviewed, 25.3% of whom reported using cannabis to treat their symptoms. Only 1.4% received legal medical cannabis.

The principal researcher and academic director of the Lambert Initiative, Professor Iain McGregor, stated according to the report:

“The survey was inspired by the experiences of the Taylor family from the Blue Mountains: father Steven Taylor was arrested for growing cannabis to alleviate the suffering of his daughters Morgan and Taylor who suffered from severe IBD and found great relief from non-intoxicating cannabis leaf juice preparations”.

McGregor further explained that this case shows that many patients suffering cannot adequately treat their disease with common medication and therefore turn to alternative treatment options.

Survey: Cannabis relieves symptoms

More than 90% of those affected said that cannabis helped improve symptoms such as pain and cramps. The quality of sleep and anxiety symptoms also improved. In contrast, the benefit for other symptoms such as bleeding, stool frequency, consistency and urgency is smaller.

Furthermore, patients receiving medical cannabis therapy were reported to have significantly improved their quality of life. In addition, cannabis clients reported that they were able to reduce the doses of their prescribed medications and needed specialist treatment less frequently.

The patients were also asked about side effects of cannabis use. These were minor and mainly limited to drowsiness and memory disorders.



Various studies have already shown that cannabidiol (CBD) can have anti-inflammatory properties. According to a media report, researchers from Tel Aviv University are now conducting several clinical studies to investigate the use of CBD in the respiratory disease, COVID-19.

As COVID-19 affects the respiratory system, researchers will administer CBD-enriched exosomes to affected patients through an inhaler. Previous studies have already shown that CBD can possibly help to regulate the immune system and inhibit inflammation. The researchers assume that the anti-inflammatory properties of CBD could repair the damaged cells through a synergistic effect. 

Another clinical trial is being conducted in COVID-19 patients currently being treated at Rabin Medical Center in Israel. Here, the researchers will combine inhalable steroids with CBD, as CBD may be able to improve the effect of the steroids. 

In addition, it will be investigated whether cannabis, with all its cannabinoids, might possibly be able to slow down or stop COVID-19. 



Researchers at Johns Hopkins University School of Medicine in Baltimore have conducted a survey of 200 people who used opioids and cannabis in the past four weeks

The results show that 125 people (62.5%) benefited from cannabis in opioid withdrawal symptoms. Women reported a greater positive effect than in men. In particular, symptoms such as sleep disturbance, trembling and anxiety were improved by the use of cannabis.

In contrast, 12 people (6%) reported that opioid withdrawal had worsened as a result of cannabis use. They reported an increase in symptoms such as watery eyes and a runny nose.

According to the researchers, the results of the study suggest that cannabis can improve opioid withdrawal symptoms and that the effect is clinically significant. The researchers further explain that cannabis only worsened the symptoms in the minority. This justifies prospective studies that investigate the effects of cannabis in opioid withdrawal symptoms.


Bergeria CL, Chicken AS, Dunn KE. The impact of naturalistic cannabis use on self-reported opioid withdrawal. J Subst Abuse Treat 2020;113:108005


Staphylococcus aureus bacterium can colonise in several people without causing any disease. However, in some cases, especially when the immune system is weakened, the bacterium can cause wound infections, pneumonia and meningitis. A particular problem here is that some variants of the bacterium are resistant to antibiotics.

In order to circumvent this resistance and increase the antibiotic effect, researchers are looking for new approaches. One of these approaches is to use so-called helper substances that are assumed to increase the effectiveness of an antibiotic.

Researchers at the University of Southern Denmark recently discovered that cannabidiol (CBD) in combination with the antibiotic bacitracin may be able to fight the Staphylococcus aureus bacterium.

In conclusion, this CBD-bacitracin combination was able to prevent the bacterium from dividing, resulting in an unstable bacterial membrane. According to the researchers, the reduced administration of antibiotics could prevent further resistances.





A study by Canadian researchers showed that cannabigerol (CBG) kills some of the most worrying antibiotic-resistant bacteria.

A team of scientists from McMaster University, Hamilton, who tested the effectiveness of cannabinoids, found that CBG showed “antibacterial activity” against MRSA, one of the most resistant microbes on the planet. The World Health Organization (WHO) has classified antibiotic resistance as “one of the greatest threats to global health”.

So far, little pharmacological research has been done on CBG, which is converted into more well-known cannabinoids such as cannabidiol (CBD) and tetrahydrocannabinol (THC) during plant growth.

MRSA, also known as methicillin-resistant Staphylococcus aureus, is a slightly widespread and common “superbug” that can cause pneumonia, meningitis and so-called carnivorous diseases.

The study describes the “mechanism of action” of CBG as an attack on the “cytoplasmic membrane” of the target bacteria. It also shows that cannabinoids are effective against gram-negative organisms whose outer membrane is permeabilized, when CBG acting on the inner membrane. Finally, the researchers show that cannabinoids in combination with polymyxin B act against multidrug-resistant gram-negative pathogens, which shows the broad therapeutic potential of cannabinoids.

The research team demonstrated the effectiveness of the substance both in the laboratory and in animal models in which mice with MRSA infections were cured. This happened after combining CBG with an established antibiotic called polymyxin B, resulting in a compound that killed the resistant bacteria.



A new study at the University Pompeu Fabra of Barcelona has highlighted the effectiveness of cannabinoid compounds found in cannabis for pain relief in women suffering with endometriosis, leading to a clinical trial launching in collaboration with the Gynecology Service of the Hospital Clinic of Barcelona. The trial will evaluate the possible benefits of the naturally occurring cannabinoid ∆9-tetrahydrocannabinol in women with endometriosis.

Endometriosis is a painful condition where the lining of the uterus grows on other parts of the organ such as the fallopian tubes. These growths affect reproductive organs and can cause pain, infertility, anxiety, depression and result in a considerable impact on quality of life. Treatment options include surgery or hormone therapy, but these are not always effective and often have significant side-effects.

The new study shows initial results from treating endometriosis in mice with cannabinoids – suggesting they can alleviate symptoms of the disease. The team studied mice with endometrial implants in their pelvis to mimic endometriosis in humans. Those with the implants were more sensitive to pain in their pelvis that can also be associated with emotional and cognitive alterations – similar to symptoms seen in some women with endometriosis.

The team next found that mice with endometriosis had similar anxiety-like symptoms experienced by some women with the condition. This was measured by the amount of time the animals spent in open areas of a maze, as those with higher anxiety levels tend not to explore too far. However, their experiments could not reveal whether THC had any significant effects in treating this anxiety.

As endometriosis can be known to impair cognitive function in some women, the team also studied memory performance in the mice. They provided the animals with two identical objects and allowed them to become familiar with them. They then replaced one of the objects and timed how long the mice spent exploring the new versus familiar object, to give an indication of what the animals remembered.

The team found that memory was impaired in the mice with endometriosis compared with those that did not have the condition. However, mice treated with THC did not show this impairment, suggesting that THC may have a protective effect.

Finally, the team studied the effects of THC on the endometrium inside and outside of the womb, and found that mice with endometriosis treated with THC for 32 days had smaller endometrial growths.




A new study has shown how fatty foods help the absorption of CBD into the body. So far, very little was known about the effect of food on CBD absorption.

A University of Minnesota study examined whether eating high-fat foods after taking CBD increased the body’s absorption of CBD. The study tested whether fasting or a high fat meal has an effect when cannabidiol oral capsules were taken by patients.

To find out what effect a fatty meal would have on CBD absorption, the research group measured CBD concentrations in epilepsy patients who were taking 99% pure CBD capsules. Concentrations from patients who took CBD on an empty stomach and a standardised fatty breakfast were compared.

The study found that: CBD exposure is vastly increased when CBD is taken with high fatty foods. When compared to fasting, taking CBD with food increased the amount of CBD in the body by four-times and the maximum amount recorded in the participants’ blood by 14-times. And: No cognitive differences were identified, which is consistent with previous studies.




Cannabis can be useful for treating migraine and other forms of headache

A study conducted by the Department of Psychology and the Translational Addiction Research Center at Washington State University, United States, showed that cannabis provides a significant reduction in headache.

The researchers will use an application (app) so that patients in medical treatment with cannabis can automatically monitor the symptoms and before using cannabis.

This technology is also intended to determine whether genetics, THC or CBD content and dose influence the outcome.

The collection of user data determined that there were 12,293 to treat headache and 7,441 for migraine. Among the first results included that “men affected greater headache reductions than women”, well, “the use of concentrates is associated with greater reductions than with flowers”.

“Inhaled cannabis reduces headache and migraine severity by approximately 50%. However, its effectiveness seems to decrease over time and patients can use increasing doses, which may develop tolerance to these effects with continuous use.”, the researchers conclude.


Logo Can Pharma SVG

CanPharma has a pharmaceutical wholesale permission according to §52a of the German Medicines Act, as well as a license to handle narcotics in the meaning of §3 of the German narcotics legislation. Furthermore, CanPharma has a GDP-certified quality assurance system.



CanPharma GmbH
Wiesbadener Str. 29
16515 Oranienburg, Germany


Rosenthaler Str. 34
10178 Berlin

Gran de Gràcia 15, 1-1
08012 Barcelona